News Website

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer - OncLive

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer OncLive

Published: Oct. 24, 2024, 3:55 p.m.

Read Full Article

Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers - BioSpace

Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers BioSpace

Published: Oct. 24, 2024, 11:46 a.m.

Read Full Article

Shock Diagnosis: Woman Discovers She’s Got Multiple Private Parts - MSN

Shock Diagnosis: Woman Discovers She’s Got Multiple Private Parts MSN

Published: Oct. 24, 2024, 11:16 a.m.

Read Full Article

Approval From European Commission With Two New Indications in Gynecologic Cancers - businesswire.com

Approval From European Commission With Two New Indications in Gynecologic Cancers businesswire.com

Published: Oct. 24, 2024, 10:45 a.m.

Read Full Article

FACT SHEET: Biden-Harris Administration Announces $110 Million in Awards from ARPA-H's Sprint for Women's Health to Accelerate New Discoveries and Innovation - The American Presidency Project

FACT SHEET: Biden-Harris Administration Announces $110 Million in Awards from ARPA-H's Sprint for Women's Health to Accelerate New Discoveries and Innovation The American Presidency Project

Published: Oct. 24, 2024, 7:05 a.m.

Read Full Article

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - PR Newswire

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation PR Newswire

Published: Oct. 24, 2024, 12:08 a.m.

Read Full Article

Professor Eva Dimitriadis leads breakthrough discovery into cause of unexplained infertility - Neos Kosmos

Professor Eva Dimitriadis leads breakthrough discovery into cause of unexplained infertility Neos Kosmos

Published: Oct. 23, 2024, 11 p.m.

Read Full Article

Prolonged Treatment for Endometriosis May Harm Live Birth Rate in IVF - Medpage Today

Prolonged Treatment for Endometriosis May Harm Live Birth Rate in IVF Medpage Today

Published: Oct. 23, 2024, 10:19 p.m.

Read Full Article

HLTH24: Jill Biden announces $110M ARPA-H funding award, prods industry to invest in women’s health - Fierce healthcare

HLTH24: Jill Biden announces $110M ARPA-H funding award, prods industry to invest in women’s health Fierce healthcare

Published: Oct. 23, 2024, 6 p.m.

Read Full Article

Association reported between ART and imprinting disorders - Contemporary Obgyn

Association reported between ART and imprinting disorders Contemporary Obgyn

Published: Oct. 23, 2024, 5:39 p.m.

Read Full Article

Latest Articles

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer - OncLive

Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers - BioSpace

Shock Diagnosis: Woman Discovers She’s Got Multiple Private Parts - MSN

Approval From European Commission With Two New Indications in Gynecologic Cancers - businesswire.com

FACT SHEET: Biden-Harris Administration Announces $110 Million in Awards from ARPA-H's Sprint for Women's Health to Accelerate New Discoveries and Innovation - The American Presidency Project

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - PR Newswire

Professor Eva Dimitriadis leads breakthrough discovery into cause of unexplained infertility - Neos Kosmos

Prolonged Treatment for Endometriosis May Harm Live Birth Rate in IVF - Medpage Today

HLTH24: Jill Biden announces $110M ARPA-H funding award, prods industry to invest in women’s health - Fierce healthcare

Association reported between ART and imprinting disorders - Contemporary Obgyn

Subscribe to Our Newsletter